Clinical trial NCT04297332: Episodic Future Thinking and Future Thinking Priming for Smoking Cessation
Official title: Promising Methods to Decrease Delay Discounting and Reduce Relapse to Smoking
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Tobacco-Related Carcinoma
Lead sponsor: Roswell Park Cancer Institute
Sponsor class: OTHER
First posted: 2020-03-05
Enrollment: 26
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: PREVENTION

Brief summary: This trial studies the main and interactive effects of episodic future thinking and future thinking priming tasks on helping participants to quit smoking. Episodic future thinking and future thinking priming tasks may decrease delay discounting rates and reduce relapse to smoking and help participants quit smoking.

Detailed description: PRIMARY OBJECTIVE:

I. To quantify the main and interactive effects of the episodic future thinking (EFT) and future thinking priming (FTP) tasks on delay discounting rate, latency to relapse, and multiple abstinence and self-regulation measures among smokers (n=76) who call a busy Quitline to quit smoking.

OUTLINE: Participants are randomized to 1 of 4 arms.

ARM I: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.

ARM II: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete an active episodic future thinking or control future thinking priming task once per week for 12 weeks, alternating every week between tasks.

ARM III: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or active future thinking priming task once per week for 12 weeks, alternating every week between tasks.

ARM IV: Participants are provided with Forever Free relapse prevention booklets and receive a 2-week supply of nicotine patches, gum, or lozenges. Participants also receive 1 proactive coaching call within 24 hours of quit date. Beginning on the quit date, participants complete a control episodic future thinking or control future thinking priming tasks once per week for 12 weeks, alternating every week between tasks.

Eligibility criteria: Inclusion Criteria:

* Smoke \>= 8 cigarettes daily
* Planning to quit in the next 14 days
* No regular use of other tobacco products
* Access to the internet
* In possession of a smartphone with text messaging capabilities
* In possession of an email address accessible at least every other day

Exclusion Criteria:

* Unable or unwilling to provide consent
* Unable to provide data to the research team after the quit date
* Current use of bupropion or varenicline
* Drinking \>= 20 alcoholic drinks per week
* Use of drugs of abuse in the past 30 days
* Living in the same household as a participant already enrolled in this study

Primary outcomes:
measure: Change in Delay discounting rate
timeFrame: Baseline, and 4 and 12 weeks after quit date
measure: Latency to relapse
timeFrame: Baseline, assessed up to 12 weeks
Secondary outcomes:
measure: Latency to first relapse
timeFrame: up to 12 weeks
measure: Number of days abstinent
timeFrame: Up to 12 weeks
measure: 7-day point prevalence abstinence rates
timeFrame: At 4 and 12 weeks after quit date
measure: Attentional, motor, and non-planning impulsiveness
timeFrame: Up to 12 weeks
measure: Behavioral inhibition and behavioral activation
timeFrame: Up to 12 weeks
measure: Self-control
timeFrame: Up to 12 weeks
measure: Ability to regulate behavior to achieve goals
timeFrame: Up to 12 weeks
Other outcomes:
Locations:
city: Buffalo
country: United States
facility: Roswell Park Cancer Institute
state: New York
Study officials:
affiliation: Roswell Park Cancer Institute
name: Christine Sheffer
role: PRINCIPAL_INVESTIGATOR
References: